Categories AlphaGraphs, Earnings, Finance
PYPL Earnings Infographic: PayPal Q4 2022 profit and revenue increase
Payment solutions firm PayPal Holdings Inc. (NASDAQ: PYPL) announced financial results for the fourth quarter of 2022, reporting higher earnings and revenues.
Fourth-quarter revenues rose 7% year-over-year to $7.4 billion amid strong growth in payment volumes. In 2022, the company invested in the platform to better serve its customers, while focusing on and streamlining the business.
The company reported adjusted earnings of $1.24 per share for the three-month period, compared to $1.11 per share in the corresponding period of last year. On a reported basis, it was a net profit of $921 million or $0.81 per share, compared to $801 million or $0.68 per share last year.
Check this space to read management/analysts’ comments on PayPal’s Q4 2022 results
“We will continue this work throughout 2023, and I am confident that we are well-positioned to utilize our unique assets to remain a market leader in digital payments,” said PayPal’s CEO Dan Schulman.
Prior Performance
_________________________________________________________________________________________________________________
Stocks you may like:
_________________________________________________________________________________________________________________
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs
